Drugs / hepatitis B antigen peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT01292421 | Feb → Dec 2013 | — | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00003434 Background | Jun 1998 → Aug 2002 | malignant pancreatic neoplasm | Duke University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hepatitis B antigen peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003434 ↗ |
| Modality | Peptide | “hepatitis B antigen peptide” NCT00003434 ↗ |
| Route | Intravenous | “Equal doses of CEA and HBsAg peptide pulsed dendritic cells are administered intravenously over 3 minutes every 4 weeks for a total of 6 doses each.” NCT00003434 ↗ |